Aalbers R, Backer V, Kava TTK, Omenaas ER, Sandström T, Jorup C, Welte T. Adjustable maintenance dosing with budesonide/formoterol compared with fixed dose salmeterol/fluticasone in moderate to severe asthma. Current Medical Research and Opinion, 2004, Vol 20 (No.2), 225-240
Global Initiative for Asthma (GINA), 2002, NIH, publication no 02-3659.
Fitzgerald JM, Sears MR, Boulet LP, Becker AB et al. Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: A five month multicentre Canadian study. Canadian Respiratory Journal, Nov/Dec 2003, Vol 10, No 8
Ställberg B, Olsson P et al. Budesonide/Formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing. Int Journal of Clinical Practice, Oct 2003, Vol 57, No 8, 656-661
Pauwels RA, Löfdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. New England Journal of Medicine 1997;337(20):1405-11.
O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, Tattersfield A. Low dose inhaled budesonide and formoterol in mild persistent asthma: The OPTIMA randomized trial. American Journal of Respiratory and Critical Care Medicine 2001;164(8):1392-7.
Zetterström O, Buhl R, Mellem H, Hedman J, O'Neill S, Ekström T. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. European Respiratory Journal 2001;18(2):262-8.
Busse WW, Chervinsky P, Condemi J, Lumry WR, Petty TL, Rennard S, Townley RG. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. Journal of Allergy and Clinical Immunology 1998;101(No 4 Pt 1):457-63.
Pauwels R, Pedersen S, Busse WW et al. Early intervention with budesonide in mild persistent asthma: a randomised, double blind trial. Lancet 2003; 361: 1071-1076.
Ringdal N, Derom E, Wåhlin-Boll E, Pauwels R. Onset and duration of action of single doses of formoterol inhaled via Turbuhaler. Respiratory Medicine 1998;92:1017-21
Ketchell RI, Jensen MW, Spina D, O'Connor BJ. Dose-related effects of formoterol on airway responsiveness to adenosine 5'-monophosphate and histamine. European Respiratory Journal 2002;19(4):611-6.
Palmqvist M, Arvidsson P, Beckman O, Peterson S, Lötvall J. Onset of Bronchodilatation of Budesonide/Formoterol vs. Salmeterol/Fluticasone in Single Inhalers. Pulmonary Pharmacology & Therapeutics, 2001, 14, 29-34
Seberova E, Andersson A. Oxis (formoterol given by Turbuhaler) showed as rapid an onset of action as salbutamol given by a pMDI. Respiratory Medicine 2000, 94, 607-611
Tötterman KJ, Huhti L, Sutinen E, Backman R, Pientinalho A, Falck M, Larsson P, Selroos O. Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients. European Respiratory Journal 1998;12(3):573-9.
Tattersfield AE, Postma DS, Barnes PJ, Svensson K, Bauer CA, O'Byrne PM, Löfdahl CG, Pauwels RA, Ullman A. Exacerbations of asthma - a descriptive study of 425 severe exacerbations. American Journal of Respiratory and Critical Care Medicine 1999;160(2):594-9.
Kips JC, O'Connor BJ, Inman MD, Svensson K, Pauwels RA, O'Byrne PM. A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. American Journal of Respiratory and Critical Care Medicine 2000;161(3):996-1001.
Ankerst J, Persson G, Weibull E. Tolerability of a high dose of budesonide/formoterol in a single inhaler in patients with asthma. Pulmonary Pharmacology and Therapeutics 2003;16(3):147-51.
Tal A, Simon G, Vermeulen JH, Petru V, Cobos N, Everard ML, de Boeck K. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatric Pulmonology 2002;34(5):342-50
Rosenhall L, Elvstrand A, Tilling B, Vinge I, Jemsby P, Ståhl E, Jerre F, Bergqvist PBF. One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort® Turbuhaler®) for the treatment of asthma. Respiratory Medicine 2003;97(6):702-8.
Ståhl E, Ribeiro LB, Sandahl G. Dose response to inhaled terbutaline powder and peak inspiratory flow through Turbuhaler in children with mild to moderate asthma. Pediatric Pulmonology 1996;22:106-10.
Brown PH, Ning AC, Greening AP, McLean A, Crompton GK. Peak inspiratory flow through Turbuhaler in acute asthma. European Respiratory Journal 1995;8:1940-1
Asking L, Malmqvist Granlund K, Lindblad T. An in-vitro comparison of two dry powder inhalers; Symbicort® Turbuhaler® and Seretide™ Diskus™. American Journal of Respiratory and Critical Care Medicine 2001;163(5 Pt 2 Suppl):A441.
Lindblad T, Malmqvist Granlund K, Rollwage U, Trofast E. Delivery characteristics of Symbicort Turbuhaler containing both budesonide and formoterol. American Journal of Respiratory and Critical Care Medicine 2001;163(5 Pt 2 Suppl):A863
Engel T, Scharling B, Skovsted B, Heinig JH. Effects, side effects and plasma concentrations of terbutaline in adult asthmatics after inhaling from a dry powder inhaler device at different inhalation flows and volumes. British Journal of Clinical Pharmacology 1992;33:439-44.
Rosenhall L, Borg S, Andersson F, Ericsson K. Budesonide/formoterol in a single inhaler (Symbicort®) reduces healthcare costs compared with separate inhalers in the treatment of asthma over 12 months. International Journal of Clinical Practice 2003;57(8):662-7
|
